Drugs for Chronic Insomnia
January 9, 2023 (Issue: 1667)
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I...more
- EL Sutton. Insomnia. Ann Intern Med 2021; 174:ITC33. doi:10.7326/AITC202103160
- MJ Sateia et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2017; 13:307. doi:10.5664/jcsm.6470
- F De Crescenzo et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 2022; 400:170. doi:10.1016/s0140-6736(22)00878-9
- Low-dose sublingual zolpidem (Intermezzo) for insomnia due to middle-of-the-night awakening. Med Lett Drugs Ther 2012; 54:25.
- BD Brielmaier. Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent. Proc (Bayl Univ Med Cent) 2006; 19:54. doi:10.1080/08998280.2006.11928127
- T Roth et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6:487. doi:10.1016/j.sleep.2005.06.004
- FDA requires lower dosing of zolpidem. Med Lett Drugs Ther 2013; 55:5.
- FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. May 14, 2013. Available at: https://bit.ly/3W1wrig. Accessed December 19, 2022.
- In brief: Lowering the dose of Lunesta. Med Lett Drugs Ther 2014; 56:48.
- N Gunja. In the zzz zone: the effects of z-drugs on human performance and driving. J Med Toxicol 2013; 9:163. doi:10.1007/s13181-013-0294-y
- N Gunja. The clinical and forensic toxicology of z-drugs. J Med Toxicol 2013; 9:155. doi:10.1007/s13181-013-0292-0
- JS Poceta. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med 2011; 7:632. doi:10.5664/jcsm.1468
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- BN Wikner et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203. doi:10.1002/pds.1457
- MJ Rapoport et al. Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry 2009; 70:663. doi:10.4088/jcp.08m04325
- B Albrecht et al. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry 2014; 48:1096. doi:10.1177/0004867414548902
- I Hernandez et al. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open 2018; 1:e180919. doi:10.1001/jamanetworkopen.2018.0919
- FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 31, 2016. Available at: http://bit.ly/3UInBW8. Accessed December 19, 2022.
- S Grigoriadis et al. Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis. Can J Psychiatry 2020; 65:821. doi:10.1177/0706743720904860
- ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. doi:10.1097/aog.0b013e31816fd910
- C Roch et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021; 238:2693. doi:10.1007/s00213-021-05954-0
- Suvorexant (Belsomra) for insomnia. Med Lett Drugs Ther 2015; 57:29.
- Lemborexant (Dayvigo) for insomnia. Med Lett Drugs Ther 2020; 62:97.
- Daridorexant (Quviviq) for insomnia. Med Lett Drugs Ther 2022; 64:107.
- A Kuriyama et al. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 2014; 15:385. doi:10.1016/j.sleep.2013.11.788
- AD Krystal et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011; 34:1433. doi:10.5665/sleep.1294
- MH Wiegand. Antidepressants for the treatment of insomnia: a suitable approach? Drugs 2008; 68:2411. doi:10.2165/0003495-200868170-00001
- WB Mendelson. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469. doi:10.4088/jcp.v66n0409
- EDA Hermes et al. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013; 36:597. doi:10.5665/sleep.2554
- SL Anderson and JP Vande Griend. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm 2014; 71:394. doi:10.2146/ajhp130221
- T Atkin et al. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev 2018; 70:197. doi:10.1124/pr.117.014381
- In Brief: Respiratory depression with gabapentinoids. Med Lett Drugs Ther 2020; 62:81.
- C Fox et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59:1477. doi:10.1111/j.1532-5415.2011.03491.x
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401. doi:10.1001/jamainternmed.2014.7663
- S Tordjman et al. Melatonin: pharmacology, functions, and therapeutic benefits. Curr Neuropharmacol 2017; 15:434. doi:10.2174/1570159x14666161228122115
- LAE Erland and PK Saxena. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med 2017; 13:275. doi:10.5664/jcsm.6462
- AB Dollins et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 1994; 91:1824. doi:10.1073/pnas.91.5.1824
- AL Lopresti et al. An investigation into an evening intake of a saffron extract (affron) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomized, double-blind, placebo-controlled, multidose study. Sleep Medicine 2021; 86:7. doi:10.1016/j.sleep.2021.08.001
- DM Taibi et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007; 11:209. doi:10.1016/j.smrv.2007.03.002
- J Sarris and GJ Byrne. A systematic review of insomnia and complementary medicine. Sleep Med Rev 2011; 15:99. doi:10.1016/j.smrv.2010.04.001
- KA Carter et al. Common sleep disorders in children. Am Fam Physician 2014; 89:368.
- AW Buckley et al. Practice guideline: treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2020; 94:392. doi:10.1212/wnl.0000000000009033
- NL Phillips et al. Behavioral interventions for sleep disturbances in children with neurological and neurodevelopmental disorders: a systematic review and meta-analysis of randomized controlled trials. Sleep 2020; 43:zsaa040. doi:10.1093/sleep/zsaa040
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
